iCardiac adds $2m to series A:
This article was originally published in Clinica
Rochester, New York-based iCardiac Technologies has brought the total raised in a series A financing to $4m, after receiving an additional $2m in an investment round led by Advantage Capital Partners and Stonehenge Capital Company. The proceeds will be used "to meet the increased interest in its technology by the pharmaceutical and biotechnology industries", says iCardiac's CEO, Mikael Totterman. The company is developing cardiac safety analysis technologies that can be used for assessing the safety profile of cardiac drugs, as well as for ECG-based cardiac diagnostic and medical device applications.
You may also be interested in...
Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.